Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep;18(3):472-478.
doi: 10.4314/ahs.v18i3.2.

Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos Nigeria

Olusola Adedeji Adejumo  1 , Bolanle Olusola-Faleye  2 , Victor Adepoju  2 , Abimbola Bowale  1 , Sunday Adesola  1 , Ayodeji Falana  1 , Henry Owuna  1 , Kehinde Otemuyiwa  1 , Shafaatu Oladega  1 , Oluwatosin Adegboye  2
Affiliations

Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos Nigeria

Olusola Adedeji Adejumo et al. Afr Health Sci. 2018 Sep.

Abstract

Background: Nigeria is one of the 30 high burden countries for drug resistant tuberculosis (DR-TB). This study assessed the prevalence and factors associated with rifampicin resistant tuberculosis (RR-TB) in a secondary referral hospital in Lagos State Nigeria.

Methods: A retrospective review of presumptive TB register of patients screened for Mycobacterium tuberculosis (MTB) and RR-TB using Xpert MTB/RIF assay at Mainland hospital between January 1 2012 and December 31 2016 was conducted.

Results: A total of 2497 clients were screened for MTB and RR-TB during the study period. The majority (51.4%) were between 25 - 44 years. Male: Female ratio was 1:0.8. Of the 2497 clients screened, MTB was detected in 942 (37.7%) out of which 220 (23.4%) had RR-TB. Age (AOR 1.8, 95%CI 1.3- 2.6, p = 0.001), symptomatic contact with DR-TB patients (AOR 3.3, 95%CI 2.1-5.1, p <0.001) and type of TB (AOR 2.9, 95% CI 1.7 - 5.0, <0.001) were associated with RR-TB after adjusting for age, gender, HIV status and symptomatic contacts with DR-TB patients.

Conclusion: The prevalence of RR-TB in new and previously treated TB patients was high in this study. Urgent steps are needed to avert an impending RR-TB epidemic.

Keywords: Lagos; Rifampicin resistance; Xpert MTB/RIF; tuberculosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Reasons for Xpert MTB/RIF assay
See this image and copyright information in PMC

References

    1. Burki T. Tuberculosis-resistance, funding, and drugs. Lancet Infect Dis. 2010;10:297–298. - PubMed
    1. World Health Organization, author. Global Tuberculosis Report 2016. Geneva, Switzerland: World Health Organization; 2016. [September 2017]. Available from www.who.int/tb/publications/global_report/en/
    1. Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, et al. Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J. 2015;45(1):150–160. - PMC - PubMed
    1. Onyedum CC, Alobu I, Ukwaja KN. Prevalence of drug-resistant tuberculosis in Nigeria: A systematic review and meta-analysis. PLoS ONE. 2017;12(7):e0180996. doi: 10.1371/journal.pone.0180996. PubMed. - DOI - PMC - PubMed
    1. Cresswell J, Codlin AJ, Andre E. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis. 2014;14:2. - PMC - PubMed

MeSH terms

LinkOut - more resources